News

Deal Announcements

Aclaris Therapeutics Nets Series B Venture Capital

Friday, October 3, 2014 5:30:00 AM PDT | VentureDeal
   Malvern, Pennsylvania  -- Pharmaceutical technology company Aclaris Therapeutics has secured $21 million in its second round of venture capital investment.

Aclaris is developing novel topical dermatological therapies.

Investors in the round included previous investors Vivo Ventures, Fidelity BioSciences and Sofinnova Ventures.

The company said it would use the funding to advance its A-101 treatment candidate through to the filing of a new drug application with the US FDA.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1